Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase I, Randomized, Double Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability and Immunogenicity of SN2001 in Healthy Adult Subjects
This is a randomized, double-blind, placebo-controlled, multiple-ascending-dose study of SN2001 in healthy adult subjects. The study is designed to evaluate the safety, tolerability and immunogenicity of SN2001.
100 Clinical Results associated with Kemi Biopharmaceuticals (Chengdu) Co., Ltd.
0 Patents (Medical) associated with Kemi Biopharmaceuticals (Chengdu) Co., Ltd.
100 Deals associated with Kemi Biopharmaceuticals (Chengdu) Co., Ltd.
100 Translational Medicine associated with Kemi Biopharmaceuticals (Chengdu) Co., Ltd.